Results from Phase II continuation studies of pegaptanib sodium (Macugen) for the treatment of diabetic retinopathy (DR) and Central Retinal Vein Occlusion (CRVO), found that the relative benefits of the treatment were maintained throughout the continuation period with no new safety signals to report.
Results from Phase II continuation studies of pegaptanib sodium (Macugen) for the treatment of diabetic retinopathy (DR) and Central Retinal Vein Occlusion (CRVO), found that the relative benefits of the treatment were maintained throughout the continuation period with no new safety signals to report.
The first trial found that, at week 36, 34% of patients with diabetic macular oedema had gained ≥10 letters of visual acuity (VA) when treated with Macugen compared with 10% of controls. Furthermore, it was also discovered that Macugen regressed the pathologic neovascularization of early proliferative DR. The relative benefits were maintained through to week 82.
The trial in patients with non-ischaemic CRVO found that Macugen improved VA and had an early effect at week 24 and, once the regular injections were stopped, these relative benefits were maintained through to week 52.
Macugen, a selective anti-VEGF inhibitor, is already approved for the treatment of wet age-related macular degeneration.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.